CAD, myocardial infarction and stroke. Prevalence, associations, impact on outcomes (according to the MERIDIAN-RO study)
https://doi.org/10.21518/2079-701X-2015-8-14-21
Abstract
The article presents the results of MERIDIAN-RO, a prospective cohort cross-sectional study with retrospective component. The study aimed to evaluate the incidence of ischemic heart disease, myocardial infarction and stroke in the working population of the Ryazan region, their association with risk factors, treatments and impact on mortality. In 2011, 1622 people (1220 urban and 402 rural) aged 25--64 years (mean age - 43,4 ± 11,4 years) 42.6% of which were males and 53.8% females, were included in the study. The cohort was observed for 36 months, the end points were evaluated annually. Considering the low incidence of CAD, myocardial infarction and stroke, the data were combined into one end point CAD/myocardial infarction/stroke. According to the study, the incidence of CAD/myocardial infarction/stroke was lower than on average in the Russian Federation. The main factors contributing to reaching the point of CAD/stroke/myocardial infarction were hypertension, CRP above 5 mg/l, fibrinogen above 4 g/l, apolipoprotein B above 180 mg/dl, anxiety/depression, family history of stroke and myocardial infarction, and obesity. CAD/myocardial infarction/stroke increased the burden on the healthcare system and the burden of CVD. This calls for the need to enhance treatment of these patients.
About the Authors
E. V. Filippov
Ryazan State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
V. S. Petrov
Ryazan State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
V. G. Okorokov
Ryazan State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
References
1. World Health Organization: Preventing chronic disease: a vital investment. 2005 World Health Organization Geneva, Switzerland.
2. Марцевич С.Ю., Кутишенко Н.П., Толпыгина С.Н. и др. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Доступно на сайте РКО по адресу: http://scardio.ru/recommendations/ approved00349/default.asp.
3. Centers for Disease Control and Prevention. Health, United States, 2010. February 16, 2011. Доступно по ссылке: http//www.cdc.gov/nchs/ hus.htm.
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038): 1329-1339.
6. Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med., 2000, 160(18): 2773-2778.
7. Bhatt Dl, Fox KA, Hacke W, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354: 1706.
8. Cram J, Jespersen J et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 19, 344(8934): 1383-9.
9. Arnold SV, Spertus JA, Tang F, et al: Statin use in outpatients with obstructive coronary artery disease. Circulation, 2011, 124: 2405-2410.
10. Braunwald's heart disease: a textbook of cardiovascular medicine [edited by] Robert O. Bonow et al. - 9th ed., Elsivier, 2011, p. 1852.
11. Cannon C, Braunwald E et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, 350: 1495-1504.
12. Pitt В et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. New Engl. J. Med., 1999, 341: 70-76.
13. Athyros VG et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin., 2002, 18: 220-228.
14. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The Safety of Rosuvastatin as Used in Common Clinical Practice. A Postmarketing Analysis. Circulation, 2005, 111: 3051-3057.
15. Михин В.П., Жиляева Ю.А. Дженерические статины в клинической практике: дешевые заменители или достойная альтернатива брендам. Аторвастатин. Архив внутренней медицины, 2012, 2(4): 72-76.
16. Mihaylova B, Briggs A, Armitage J, et al: Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006; 333:1145.
Review
For citations:
Filippov EV, Petrov VS, Okorokov VG. CAD, myocardial infarction and stroke. Prevalence, associations, impact on outcomes (according to the MERIDIAN-RO study). Meditsinskiy sovet = Medical Council. 2015;(8):14-21. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-14-21
Views:
540
Email this article 